glp-1 news 2025 november Weight-Loss Drug Demonstration Begins July 2026 What's next for GLP-1 innovation:

Furthermore, it significantly decreased aldosterone concentrations, a known predictor of increased cardiovascular mortality risk, which would indicate AT1R blockade ( Finally, the prevalence of primary aldosteronism (PA), the most common form of secondary hypertension, is reported to be 11-14% in patients with diabetes and hypertension

J., Flatt, P

Genetic factors identified through the Precision Peptide Genetic Test may reveal why you're sensitive to this side effectvariants in GLP1R and GIPR genes affect how quickly your body processes GLP-1 agonists, influencing fermentation patterns in your gut

Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ

The truth is, GLP-1s are not for everyone clinical studies have found that just over 10% of patients do not lose weight on semaglutide, while others cant tolerate certain side effects and have to stop taking the drug

Gether IM, Nexoe-Larsen C, Knop FK